Logo image of HURA

TUHURA BIOSCIENCES INC (HURA) Stock Price, Quote, News and Overview

NASDAQ:HURA - Nasdaq - US8989201038 - Common Stock - Currency: USD

2.3  -0.13 (-5.35%)

After market: 2.34 +0.04 (+1.74%)

HURA Quote, Performance and Key Statistics

TUHURA BIOSCIENCES INC

NASDAQ:HURA (8/8/2025, 8:00:02 PM)

After market: 2.34 +0.04 (+1.74%)

2.3

-0.13 (-5.35%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap107.06M
Shares46.55M
Float28.22M
Yearly Dividend0
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)10-06 2025-10-06/amc
IPO07-12 2016-07-12


HURA short term performance overview.The bars show the price performance of HURA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

HURA long term performance overview.The bars show the price performance of HURA in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of HURA is 2.3 USD.

TUHURA BIOSCIENCES INC / HURA Daily stock chart

HURA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.7 349.84B
AMGN AMGEN INC 13.22 154.98B
GILD GILEAD SCIENCES INC 15.43 148.54B
VRTX VERTEX PHARMACEUTICALS INC 21.64 94.13B
REGN REGENERON PHARMACEUTICALS 12.34 60.79B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 57.23B
ARGX ARGENX SE - ADR 71.39 40.50B
ONC BEONE MEDICINES LTD-ADR 4.5 31.19B
BNTX BIONTECH SE-ADR N/A 26.84B
SMMT SUMMIT THERAPEUTICS INC N/A 21.28B
INSM INSMED INC N/A 20.78B
NTRA NATERA INC N/A 20.75B

About HURA

Company Profile

HURA logo image TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 19 full-time employees. The company went IPO on 2016-07-12. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The company is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.

Company Info

TUHURA BIOSCIENCES INC

10500 University Center Dr., Suite 110

Tampa FLORIDA US

Employees: 19

HURA Company Website

HURA Investor Relations

Phone: 18138756600

TUHURA BIOSCIENCES INC / HURA FAQ

What is the stock price of TUHURA BIOSCIENCES INC today?

The current stock price of HURA is 2.3 USD. The price decreased by -5.35% in the last trading session.


What is the ticker symbol for TUHURA BIOSCIENCES INC stock?

The exchange symbol of TUHURA BIOSCIENCES INC is HURA and it is listed on the Nasdaq exchange.


On which exchange is HURA stock listed?

HURA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TUHURA BIOSCIENCES INC stock?

8 analysts have analysed HURA and the average price target is 12.33 USD. This implies a price increase of 435.87% is expected in the next year compared to the current price of 2.3. Check the TUHURA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TUHURA BIOSCIENCES INC worth?

TUHURA BIOSCIENCES INC (HURA) has a market capitalization of 107.06M USD. This makes HURA a Micro Cap stock.


How many employees does TUHURA BIOSCIENCES INC have?

TUHURA BIOSCIENCES INC (HURA) currently has 19 employees.


What are the support and resistance levels for TUHURA BIOSCIENCES INC (HURA) stock?

TUHURA BIOSCIENCES INC (HURA) has a support level at 2.27 and a resistance level at 2.55. Check the full technical report for a detailed analysis of HURA support and resistance levels.


Should I buy TUHURA BIOSCIENCES INC (HURA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TUHURA BIOSCIENCES INC (HURA) stock pay dividends?

HURA does not pay a dividend.


When does TUHURA BIOSCIENCES INC (HURA) report earnings?

TUHURA BIOSCIENCES INC (HURA) will report earnings on 2025-10-06, after the market close.


What is the Price/Earnings (PE) ratio of TUHURA BIOSCIENCES INC (HURA)?

TUHURA BIOSCIENCES INC (HURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.1).


What is the Short Interest ratio of TUHURA BIOSCIENCES INC (HURA) stock?

The outstanding short interest for TUHURA BIOSCIENCES INC (HURA) is 9.37% of its float. Check the ownership tab for more information on the HURA short interest.


HURA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

HURA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to HURA. The financial health of HURA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HURA Financial Highlights

Over the last trailing twelve months HURA reported a non-GAAP Earnings per Share(EPS) of -4.1. The EPS increased by 27.01% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -216.15%
ROE -321.03%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%91.8%
Sales Q2Q%N/A
EPS 1Y (TTM)27.01%
Revenue 1Y (TTM)N/A

HURA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to HURA. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners8.43%
Ins Owners32.23%
Short Float %9.37%
Short Ratio8.86
Analysts
Analysts82.5
Price Target12.33 (436.09%)
EPS Next Y-18.84%
Revenue Next YearN/A